We developed our biotech with every asthma sufferer at heart, and with the following question in mind: how could we turn our cutting-edge knowledge of allergies and precision medicine into a life-changing reality that would allow them to enjoy life to the full?
ANGANY is a privately-held, clinical-stage pharmaceutical company dedicated to offering a new, sustainable and curative approach to people suffering from allergic asthma.
Drawing on 30 years of research in biotechnology, immunology and vaccinology, and after more than $30M ANGANY is a private, clinical-stage pharmaceutical company dedicated to offering a new, sustainable and curative approach to allergic asthma.
Backed by 30 years of research in biotechnology, immunology and vaccinology, and more than $30 million in R&D investments, ANGANY has developed an exclusive therapeutic platform based on synthetic biology. This self-adjuvant vector, the eBioparticle™, has demonstrated at preclinical level the possibility of reversing the allergic dynamics at the root of allergic asthma.
An initial clinical study at Imperial College London confirmed the product’s safety and hypoallergenicity, marking a break with existing immunotherapy products. ANGANY has also developed a third-generation plant production platform that is flexible, fast and easy to scale up.
ANGANY’s aim is to provide sustainable solutions in a context where all too often allergy sufferers still have to rely on medication that merely alleviates symptoms. ANGANY has developed a simple-to-administer form of immunotherapy, which we expect to be safe and provide lasting protection. Our aim is to reverse a person’s allergic dynamics to counteract asthma, a major chronic complication. Asthma remains a significant therapeutic challenge, presenting patients and their doctors with a choice between symptomatic treatments to be taken regularly on a daily basis, or sometimes, in more severe cases, very costly monoclonal antibody treatments.
ANGANY proposes to take this important step: freeing people affected by allergic asthma by reversing the underlying immune dynamics, and enabling them to enjoy life to the full again!
ANGANY has chosen to develop a product designed to provide a lasting cure for cat allergy. Indeed, 40% of children and 30% of adults with asthma are also allergic to cats. This allergen, which is easily dispersed in the air, is difficult to avoid in today’s society. Small in size, it bypasses the nasal filter and reaches deep into the lungs, helping to trigger allergic asthma. The US market for the product specifically targeting this allergy is estimated at over 400,000 patients. ANGANY’s unique approach, at the intersection of biologics and allergenic desensitization, positions the company strategically to address this growing market with no direct competition.
ANGANY anticipates that its therapeutic platform will also find direct applications in other fields such as cancer, autoimmune, infectious and other diseases, in both human and animal health.
